Every round on record, with the sources behind each and the investors on them.
A biopharmaceutical company focused on developing therapies for kidney disease
r1therapeutics.comLinkedInRedwood City, CABiotechPublic company
2 sources · checked 7 times, last 21h ago
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The source identifies Samsara BioCapital as providing the added money but does not call it a lead investor.; not on the page it cites, so not applied: date
Verification conflict: amount $3M vs $80.5 million (https://r1therapeutics.com/newsroom/press-releases/r1-therapeutics-expands-series-a)
7 sources
The source's Redwood City dateline does not state the company's headquarters.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A | $3M $80.5M to date | 2026-09-30 | not stated | No recent discussion |
2 sources · checked 7 times, last 21h ago [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 of 2 sources The source identifies Samsara BioCapital as providing the added money but does not call it a lead investor.; not on the page it cites, so not applied: date Verification conflict: amount $3M vs $80.5 million (https://r1therapeutics.com/newsroom/press-releases/r1-therapeutics-expands-series-a) | ||||
R1 Therapeutics develops first-in-class kidney-disease medicines, beginning with AP306 for people on dialysis who have chronic-kidney-disease-related hyperphosphatemia.
Hyperphosphatemia is a serious, poorly controlled complication of chronic kidney disease in dialysis patients: existing phosphate binders can require 9–15 pills per day, are poorly tolerated, and more than 70% of U.S. dialysis patients fail to achieve normal phosphate levels. R1 has expanded its Series A to $80.5 million to advance AP306, which blocks active phosphate transport through three gut transporters, while its global Phase 2b trial is underway with topline data expected in the first half of 2027.
Checked against 9 sources on Sep 30
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $77.5M $80.5M to date | 2026-03-17 | Abingworth, DaVita Venture Group, F-Prime | No recent discussion |
7 sources [ VERIFIED ] read against 1 of 7 sources The source's Redwood City dateline does not state the company's headquarters. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]7 pages read: endpoints.news, pulse2.com, r1therapeutics.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 of 7 sources·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
Also named as backers in company research: SNMA Capital (previously Symbiosis Capital Management)